Cite
Aghdam N, Lischalk JW, Marin MP, et al. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Front Oncol. 2021;11:728519doi: 10.3389/fonc.2021.728519.
Aghdam, N., Lischalk, J. W., Marin, M. P., Hall, C., O'Connor, T., Campbell, L., Suy, S., Collins, S. P., Margolis, M., Krochmal, R., Anderson, E., & Collins, B. T. (2021). Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Frontiers in oncology, 11728519. https://doi.org/10.3389/fonc.2021.728519
Aghdam, Nima, et al. "Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy." Frontiers in oncology vol. 11 (2021): 728519. doi: https://doi.org/10.3389/fonc.2021.728519
Aghdam N, Lischalk JW, Marin MP, Hall C, O'Connor T, Campbell L, Suy S, Collins SP, Margolis M, Krochmal R, Anderson E, Collins BT. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Front Oncol. 2021 Nov 29;11:728519. doi: 10.3389/fonc.2021.728519. eCollection 2021. PMID: 34912703; PMCID: PMC8667471.
Copy
Download .nbib